MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
75 76 Next >
News headline image
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Large Cap BIopharmaceuticals Overview ↗
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
News headline image
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy. ↗
There's probably a big enough pie here for everyone to get a slice. 
Via The Motley Fool
News headline image
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Stocks Seeing Relentless Buying Pressure; Bonds Are Not ↗
Relentless buying pressure, to the degree that we saw in Q4 last year, is evidence of strong underlying demand for stocks. Meanwhile, after a 40-year drawdown, the 50-week rate of change for US 30-year... 
Via Talk Markets
News headline image
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
From AstraZeneca
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
From AstraZeneca
Via Business Wire
News headline image
3 No-Brainer Stocks to Buy in June ↗
Now is the time to invest in these great stocks. 
Via The Motley Fool
News headline image
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 ↗
AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years. 
Via The Motley Fool
Topics Stocks
News headline image
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug ↗
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases. 
Via Benzinga
News headline image
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock ↗
Both businesses have road maps for the future, but one is better. 
Via The Motley Fool
News headline image
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? ↗
Its new strategic roadmap aims to catapult the company forward. 
Via The Motley Fool
News headline image
Cellectis Reports Financial Results for First Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. 
Via Benzinga
News headline image
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report ↗
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers. 
Via Benzinga
News headline image
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings ↗
Via Talk Markets
News headline image
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies ↗
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq. 
Via Benzinga
Topics Lawsuit
News headline image
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
From AstraZeneca
Via Business Wire
News headline image
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity ↗
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later... 
Via Benzinga
News headline image
The RBNZ Maintained Its Hawkish Bias, Leaving The Interest Rate At 5.5% ↗
The Reserve Bank of New Zealand kept the official cash rate at 5.5% during its May 2024 policy meeting, extending the rate pause for the 7th straight time and confirming market expectations. 
Via Talk Markets
News headline image
AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion ↗
AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new... 
Via Benzinga
News headline image
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
From AstraZeneca
Via Business Wire
News headline image
Large Cap Biopharmaceuticals Performance ↗
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
News headline image
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population ↗
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with... 
Via Benzinga
News headline image
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute ↗
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment. 
Via Benzinga
Topics Intellectual Property
News headline image
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows ↗
AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various... 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story